Status:
COMPLETED
Using Telmisartan Alone or Combination of Telmisartan -HCTZ in the Treatment of Mild to Moderate Essential Hypertension
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Hypertension
Eligibility:
All Genders
18+ years
Brief Summary
The aim of this therapeutic observation is to demonstrate the efficacy and safety of telmisartan or telmisartan and HCTZ in the treatment of patients with mild-to-moderate essential hypertension under...
Detailed Description
Study 502.465(NCT00638911) was planned and conducted as 6 independent substudies with varying country participation. One study database, a data management plan or a TSAP were not planned and do not ex...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- 1\. Male or female patients over the age of 18 years, with mild-to-moderate essential hypertension with values of mean morning seated diastolic BP more than 90 mmHg and less than 109 mmHg and or mean morning seated systolic BP more than 140 mmHg and less than 180 mmHg
- newly diagnosed patients
- patients failing to reach target blood pressure of less than 140 on 90 on their current antihypertensive treatment
- Exclusion criteria:
- Pre-menopausal women who do not use adequate contraception who are pregnant or nursing
- Cholestasis and biliary obstructive disorders
- Severe hepatic impairment
- Severe renal impairment creatinine clearance less than 30 ml pro min
- Refractory hypokalaemia hypercalcaemia
- Known hypersensitivity to any component in the formulation of Micardis/Micardis Plus
Exclusion
Key Trial Info
Start Date :
September 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
33247 Patients enrolled
Trial Details
Trial ID
NCT00638911
Start Date
September 1 2004
Last Update
May 21 2012
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.